Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk

International Angiology

Volumn 30, Issue 4, 2011, Pages 366-374

  Boh, M ^a   Opolski, G ^b   Poredos P ^c   Ceska R ^d   Jezovnik, M K ^c  

^a KRKA D D   (Slovenia)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Lipids; Risk assessment; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORIS; ATORVASTATIN; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GENERIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FLATULENCE; HUMAN; HYPERTENSION; INSOMNIA; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; CORONARY DISEASE; CZECH REPUBLIC; DOUBLE-BLIND METHOD; DRUGS, GENERIC; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POLAND; PYRROLES; THERAPEUTIC EQUIVALENCY; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054775032     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
2. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981;141:1128-31. (Pubitemid 11017493)
3. Genest J Jr, Cohn J. Plasma triglyceride-rich lipoprotein and high density lipoproteins disorders associated with atherosclerosis. J Investig Med 1998;46:351-8. (Pubitemid 128455003)
4. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B. (Pubitemid 28113939)
5. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971;74:1-12.
6. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19(Suppl A):A2-11.
7. Isles CG, Paterson JR. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. QJM 2000;93:567-74.
8. Assmann G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. In: Assmann G, editor. Lipid metabolism disorders and coronary heart disease. München: MMV Medizin Verlag; 1993. p. 19-68.
9. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
10. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-6. (Pubitemid 29314237)
11. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Beider R et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Pubitemid 38477774)
12. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. (Pubitemid 40471450)
13. Cullen P, von Eckardstein A, Assmann G. Diagnosis and management of new cardiovascular risk factors. Eur Heart J 1998;19(Suppl O):O13-9. (Pubitemid 28524034)
14. Assmann G, Carmena R, Cullen P, Fruchart JC, Jossa F, Lewis B et al. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease. Circulation 1999;100:1930-8.
15. The International Task Force for Prevention of Coronary Heart Disease 2010. [cited 2011 May 24]. Available at: http://www.chd-taskforce.com/
16. Hwang IK. Design issues in noninferiority/equivalence trials Drug Inf J 1999;33:1205-18.
17. Hauschke D. Choice of delta: a special case. Drug Inf J 2001;35:875-9. (Pubitemid 32825955)
18. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;61:1835-81. (Pubitemid 32980510)
19. Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998;32:1030-43. (Pubitemid 28498464)
20. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004;26:1388-99. (Pubitemid 39572153)
21. Narita Y, Kitazoe Y, Kurihara Y, Okuhara Y, Takamatsu K, Saito N et al. Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels. Eur J Clin Pharmacol 1997;52:461-3. (Pubitemid 27395645)
22. Miserez AR, Rossi FA, Keller U. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects. Eur J Clin Pharmacol 1994;46:107-14. (Pubitemid 24101325)
23. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92. (Pubitemid 29451714)
24. Pocket guide to prevention of coronary heart disease. Grünwald: Börm Bruckmeier Verlag GmbH; 2003.
25. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6. (Pubitemid 30002395)
26. Hermida RC, Calvo C, Ayala DE, Lopez JE. OR-6: Administration time-dependent efficacy of valsartan-atorvastatin combination in hyperlipidemic patients with essential hypertension. Am J Hypertens 2005;18:2A-A.
27. Calvo C, Hermida RC, Ayala DE, Covelo M, Lopez JE. OR-5: Atorvastatin reduces ambulatory blood pressure in hyperlipidemic patients with untreated grade 1 essential hypertension. Am J Hypertens 2005;18:2A-A.
28. Kwang Kon K, Michael JQ, Myron AW. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 2008;196:1-8.
29. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3. (Pubitemid 28391836)
30. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. (Pubitemid 36158034)
31. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38. (Pubitemid 40075678)
32. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511. (Pubitemid 36158056)
33. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009;38:217-31.
34. Koenig W Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol 2005;98:199-206. (Pubitemid 40431164)